Ihab Hajjar1,2, Kristine J Rosenberger1, Ambar Kulshreshtha3, Hilsa N Ayonayon4, Kristine Yaffe4,5,6, Felicia C Goldstein2. 1. Department of Medicine, Emory School of Medicine, Atlanta, Georgia. 2. Department of Neurology, Emory School of Medicine, Atlanta, Georgia. 3. Department of Family and Preventive Medicine, Emory School of Medicine, Atlanta, Georgia. 4. Department of Epidemiology and Biostatistics, University of California, San Francisco. 5. Department of Neurology, University of California, San Francisco. 6. Department of Psychiatry, University of California, San Francisco.
Abstract
Importance: The Eighth Joint National Committee (JNC-8) recommended treating systolic blood pressure (SBP) to a target below 150 mm Hg in older adults, whereas data from the Systolic Blood Pressure Intervention Trial (SPRINT) suggested that a SBP level of lower than 120 mm Hg decreases cardiovascular event rates. Target SBP guidelines have not addressed the potential that black patients may have greater morbidity and mortality from hypertension, especially with regard to cognitive outcomes. The association of these discordant SBP targets with cognition and differences by race have not been systematically evaluated in the same population. Objectives: To assess the long-term outcomes of the various recommended SBP levels and to determine if racial differences exist based on long-term cognitive trajectories. Design, Setting, and Participants: A total of 1657 cognitively intact older adults receiving treatment for hypertension were studied from 1997 to 2007 in the Health Aging and Body Composition study. Data analysis was conducted from October 1, 2016, to January 1, 2017. Main Outcomes and Measures: Cognition was assessed using the Modified Mini-Mental State Examination (3MSE) 4 times and the Digit Symbol Substitution Test (DSST) 5 times. At each visit, participants were classified as having an SBP level of 120 mm Hg or lower, 121 to 139 mm Hg, 140 to 149 mm Hg, or 150 mm Hg or higher based on the mean SBP level of 2 seated readings. Mixed models assessed the association of SBP levels with 10-year cognitive trajectories. The impact of race was tested using a race interaction term. Results: During the 10-year study period, among the 1657 individuals (908 women and 784 black patients; mean [SE] age, 73.7 [0.1] years), there was a differential decrease in 3MSE and DSST scores by the SBP levels, with the greatest decrease in the group with SBP levels of 150 mm Hg or higher (adjusted decrease was 3.7 for 3MSE and 6.2 for DSST) and the lowest decrease in the group with SBP levels of 120 mm Hg or lower (adjusted decrease was 3.0 for 3MSE and 5.0 for DSST) (P < .001 for both). Compared with white patients, black patients had a greater difference between the higher and lower SBP levels in the decrease in cognition; adjusted differences between the group with SBP levels of 150 mm Hg or higher and the group with SBP levels of 120 mm Hg or lower were -0.05 in white patients and -0.08 in black patients for 3MSE (P = .03) and -0.07 in white patients and -0.13 in black patients for DSST (P = .05). Conclusions and Relevance: For patients 70 years of age or older receiving treatment for hypertension, a SPRINT SBP level of 120 mm Hg or lower was not associated with worsening cognitive outcome and may be superior to the JNC-8 target for cognition. Lower SBP treatment levels may result in improved cognition in black patients.
Importance: The Eighth Joint National Committee (JNC-8) recommended treating systolic blood pressure (SBP) to a target below 150 mm Hg in older adults, whereas data from the Systolic Blood Pressure Intervention Trial (SPRINT) suggested that a SBP level of lower than 120 mm Hg decreases cardiovascular event rates. Target SBP guidelines have not addressed the potential that black patients may have greater morbidity and mortality from hypertension, especially with regard to cognitive outcomes. The association of these discordant SBP targets with cognition and differences by race have not been systematically evaluated in the same population. Objectives: To assess the long-term outcomes of the various recommended SBP levels and to determine if racial differences exist based on long-term cognitive trajectories. Design, Setting, and Participants: A total of 1657 cognitively intact older adults receiving treatment for hypertension were studied from 1997 to 2007 in the Health Aging and Body Composition study. Data analysis was conducted from October 1, 2016, to January 1, 2017. Main Outcomes and Measures: Cognition was assessed using the Modified Mini-Mental State Examination (3MSE) 4 times and the Digit Symbol Substitution Test (DSST) 5 times. At each visit, participants were classified as having an SBP level of 120 mm Hg or lower, 121 to 139 mm Hg, 140 to 149 mm Hg, or 150 mm Hg or higher based on the mean SBP level of 2 seated readings. Mixed models assessed the association of SBP levels with 10-year cognitive trajectories. The impact of race was tested using a race interaction term. Results: During the 10-year study period, among the 1657 individuals (908 women and 784 black patients; mean [SE] age, 73.7 [0.1] years), there was a differential decrease in 3MSE and DSST scores by the SBP levels, with the greatest decrease in the group with SBP levels of 150 mm Hg or higher (adjusted decrease was 3.7 for 3MSE and 6.2 for DSST) and the lowest decrease in the group with SBP levels of 120 mm Hg or lower (adjusted decrease was 3.0 for 3MSE and 5.0 for DSST) (P < .001 for both). Compared with white patients, black patients had a greater difference between the higher and lower SBP levels in the decrease in cognition; adjusted differences between the group with SBP levels of 150 mm Hg or higher and the group with SBP levels of 120 mm Hg or lower were -0.05 in white patients and -0.08 in black patients for 3MSE (P = .03) and -0.07 in white patients and -0.13 in black patients for DSST (P = .05). Conclusions and Relevance: For patients 70 years of age or older receiving treatment for hypertension, a SPRINT SBP level of 120 mm Hg or lower was not associated with worsening cognitive outcome and may be superior to the JNC-8 target for cognition. Lower SBP treatment levels may result in improved cognition in black patients.
Authors: I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg Journal: Lancet Date: 1996-04-27 Impact factor: 79.321
Authors: M Kivipelto; E L Helkala; T Hänninen; M P Laakso; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen Journal: Neurology Date: 2001-06-26 Impact factor: 9.910
Authors: Rebecca F Gottesman; Andrea L C Schneider; Marilyn Albert; Alvaro Alonso; Karen Bandeen-Roche; Laura Coker; Josef Coresh; David Knopman; Melinda C Power; Andreea Rawlings; A Richey Sharrett; Lisa M Wruck; Thomas H Mosley Journal: JAMA Neurol Date: 2014-10 Impact factor: 18.302
Authors: Jeffrey A Cutler; Paul D Sorlie; Michael Wolz; Thomas Thom; Larry E Fields; Edward J Roccella Journal: Hypertension Date: 2008-10-13 Impact factor: 10.190
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Nigel S Beckett; Ruth Peters; Astrid E Fletcher; Jan A Staessen; Lisheng Liu; Dan Dumitrascu; Vassil Stoyanovsky; Riitta L Antikainen; Yuri Nikitin; Craig Anderson; Alli Belhani; Françoise Forette; Chakravarthi Rajkumar; Lutgarde Thijs; Winston Banya; Christopher J Bulpitt Journal: N Engl J Med Date: 2008-03-31 Impact factor: 91.245
Authors: Deborah A Levine; Andrzej T Galecki; Kenneth M Langa; Frederick W Unverzagt; Mohammed U Kabeto; Bruno Giordani; Mary Cushman; Leslie A McClure; Monika M Safford; Virginia G Wadley Journal: Hypertension Date: 2019-02 Impact factor: 10.190
Authors: Pasquale Palmiero; Annapaola Zito; Maria Maiello; Annagrazia Cecere; Anna Vittoria Mattioli; Roberto Pedrinelli; Pietro Scicchitano; Marco Matteo Ciccone Journal: Curr Hypertens Rev Date: 2019
Authors: Deborah A Levine; Alden L Gross; Emily M Briceño; Nicholas Tilton; Mohammed U Kabeto; Stephanie M Hingtgen; Bruno J Giordani; Jeremy B Sussman; Rodney A Hayward; James F Burke; Mitchell S V Elkind; Jennifer J Manly; Andrew E Moran; Erin R Kulick; Rebecca F Gottesman; Keenan A Walker; Yuichiro Yano; Darrell J Gaskin; Stephen Sidney; Kristine Yaffe; Ralph L Sacco; Clinton B Wright; Veronique L Roger; Norrina Bai Allen; Andrzej T Galecki Journal: JAMA Neurol Date: 2020-07-01 Impact factor: 29.907